Abstract
In 7 of 8 children with idiopathic pulmonary arterial hypertension treated with intravenous epoprostenol for >1 year, concomitant use of bosentan allowed a reduction of epoprostenol and decreased its associated side effects without deterioration of clinical and hemodynamic parameters. In 3 children with normal or near-normal pulmonary artery pressure on epoprostenol, the addition of bosentan allowed discontinuation of epoprostenol and stabilization of hemodynamics for up to 1 year.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Antihypertensive Agents / administration & dosage*
-
Antihypertensive Agents / adverse effects
-
Blood Pressure / physiology
-
Bosentan
-
Child
-
Child, Preschool
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Epoprostenol / administration & dosage*
-
Epoprostenol / adverse effects
-
Female
-
Humans
-
Hypertension, Pulmonary / drug therapy*
-
Hypertension, Pulmonary / physiopathology*
-
Male
-
Sulfonamides / administration & dosage*
-
Vascular Resistance / physiology
Substances
-
Antihypertensive Agents
-
Sulfonamides
-
Epoprostenol
-
Bosentan